HSK34890

HSK34890 is an orally administered small molecule drug developed by Tibet Haisco Pharmaceutical. It is being investigated for the treatment of type 2 diabetes mellitus, with its primary therapeutic area in endocrinology and metabolic diseases. The mechanism of action has not been publicly disclosed as of June 2025, and it does not represent a novel mechanism based on available sources. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy subjects and patients with type 2 diabetes over multiple dosing regimens[1][2][3][4]. As of the latest updates, no adverse events or approvals have been reported.